Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse for at vurdere ændringer i sygdomsaktivitet, uønskede hændelser og hvordan stoffet bevæger sig gennem kroppen hos voksne deltagere, der lever med humant immundefektvirus (HIV), der modtager intravenøs (IV) infusion af Buigalimab og/eller ABBV-382

4. november 2026 opdateret af: AbbVie

En fase 2, multicenter, randomiseret, dobbeltblind, placebokontrolleret undersøgelse til evaluering af effektivitet, sikkerhed, tolerabilitet og farmakokinetik af Buigalimab og/eller ABBV-382 hos mennesker, der lever med hiv på stabil antiretroviral terapi, der gennemgår afbrydelse af analytisk behandling

Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV disease is considered to be a chronic disease requiring lifelong therapy. The purpose of this study is to assess change in disease activity, adverse events, tolerability, and how the drug moves through the body.

Budigalimab and ABBV-382 are investigational drugs being developed for the treatment of HIV disease. In Part 1, participants are placed in 1 of 5 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 7 chance that participants will be assigned to placebo (A placebo is not a drug and it is not expected to have any chemical effects on your body and it is not designed to treat any disease or illness). In Part 2, eligible participants will be placed in an open-label arm to receive Budigalimab. Approximately 160 adult participants living with HIV disease on stable antiretroviral therapy (ART) willing to undergo Analytical Treatment Interruption (ATI) will be enrolled at approximately 90 sites worldwide.

In Part 1, participants will receive 4 doses of intravenous (IV) budigalimab or placebo combined with 3 doses of IV ABBV-382 or placebo for an 8 week dosing period. In Part 2, participants will receive 4 doses of open-label subcutaneous (SC) Budigalimab for a 6 week dosing period. Participants need to be stable on antiretroviral therapy to participate in the study. If participant qualifies to the study, on the day they receive the first injection, participants will be asked to stop antiretroviral medications (also referred to as analytical treatment interruption or ATI) for 112 weeks or until meeting specific criteria to restart antiretroviral medications. Participants will undergo a closely monitored ART interruption. Protocol-defined ART restart criteria includes participant's request. Participants will be followed for up to approximately 112 weeks.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. There will be an option for virtual or home health visits for some of the follow-up visits. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

163

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Brussels Capital
      • Anderlecht, Brussels Capital, Belgien, 1070
        • Universite Libre de Bruxelles - Hopital Erasme /ID# 257433
      • Brussels, Brussels Capital, Belgien, 1000
        • CHU Saint Pierre /ID# 257447
      • Brussels, Brussels Capital, Belgien, 1200
        • Cliniques Universitaires UCL Saint-Luc /ID# 257444
    • Oost-Vlaanderen
      • Ghent, Oost-Vlaanderen, Belgien, 9000
        • UZ Gent /ID# 257446
    • São Paulo
      • São Paulo, São Paulo, Brasilien, 04037-030
        • Ricardo Diaz Scientific Solution /ID# 257335
    • British Columbia
      • Vancouver, British Columbia, Canada, V6Z 2T1
        • Spectrum Health Vancouver /ID# 260791
    • Ontario
      • Ottawa, Ontario, Canada, K1H 8L6
        • Ottawa Hospital Research Institute /ID# 256993
      • Toronto, Ontario, Canada, M5G 2C4
        • Duplicate_Toronto General Hospital /ID# 256994
    • Quebec
      • Montreal, Quebec, Canada, H4A 3J1
        • McGill University Health Centre - Glen Site. /ID# 256992
      • Québec, Quebec, Canada, G1V 4G2
        • CHU de Quebec-Université Laval hôpital CHUL /ID# 261611
    • Saskatchewan
      • Regina, Saskatchewan, Canada, S4P 0W5
        • Regina General Hospital - Infectious Disease Clinic /ID# 260243
    • Greater London
      • London, Greater London, Det Forenede Kongerige, NW3 2QG
        • Royal Free Hospital /ID# 257453
      • London, Greater London, Det Forenede Kongerige, SE1 9RT
        • Dup_Guys and St Thomas NHS Foundation Trust - Guy's Hospital /ID# 257761
    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35222-2309
        • University of Alabama at Birmingham, 1917 Research Clinic /ID# 257549
    • California
      • Bakersfield, California, Forenede Stater, 93301
        • Franco Felizarta, Md /Id# 256927
      • Beverly Hills, California, Forenede Stater, 90211
        • AHF Research Center /ID# 257025
      • Long Beach, California, Forenede Stater, 90813-3267
        • Long Beach Education and Research Consultants /ID# 257552
      • Los Angeles, California, Forenede Stater, 90027
        • AHF Healthcare Center- Hollywood /ID# 257026
      • Los Angeles, California, Forenede Stater, 90028-6213
        • Los Angeles LGBT Center /ID# 258407
      • Los Angeles, California, Forenede Stater, 90036
        • Ruane Clinical Research Group /ID# 256932
      • Palm Springs, California, Forenede Stater, 92262
        • Palmtree Clinical Research Inc. /Id# 258409
      • San Francisco, California, Forenede Stater, 94102
        • Optimus Medical /ID# 257182
      • San Francisco, California, Forenede Stater, 94115-3037
        • Quest Clinical Research /ID# 256928
    • District of Columbia
      • Washington D.C., District of Columbia, Forenede Stater, 20017
        • Washington Health Institute /ID# 259336
    • Florida
      • DeLand, Florida, Forenede Stater, 32720-0920
        • Midland Florida Clinical Research Center /ID# 257101
      • Fort Lauderdale, Florida, Forenede Stater, 33308
        • Ahf Healthcare Center - Northpoint /ID# 256934
      • Ft. Pierce, Florida, Forenede Stater, 34982
        • Midway Immunology and Research Center /ID# 256930
      • Miami, Florida, Forenede Stater, 33147
        • Advanced Pharma CR, LLC /ID# 259335
      • Orlando, Florida, Forenede Stater, 32803
        • Orlando Immunology Center /ID# 256931
      • Orlando, Florida, Forenede Stater, 32806-3300
        • Bliss Health /ID# 257827
      • Tampa, Florida, Forenede Stater, 33614
        • Baycare Medical Group - Tampa /ID# 256953
      • Vero Beach, Florida, Forenede Stater, 32960-6541
        • The Pierone Research Institute /ID# 257022
      • West Palm Beach, Florida, Forenede Stater, 33407
        • Triple O Research Institute /ID# 256929
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30308
        • Winship At Emory University Hospital Midtown /ID# 258410
      • Decatur, Georgia, Forenede Stater, 30033
        • Metro Infectious Disease Consultants /ID# 256955
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60613-2010
        • Howard Brown Health Center /ID# 257485
    • Massachusetts
      • Springfield, Massachusetts, Forenede Stater, 01105-1406
        • Claudia T. Martorell MD LLC dba The Research Institute /ID# 259155
    • Missouri
      • Kansas City, Missouri, Forenede Stater, 64111
        • KC CARE Health Center - Midtown South /ID# 257178
    • Nevada
      • Las Vegas, Nevada, Forenede Stater, 89106
        • Las Vegas Research Center /ID# 257619
    • New Jersey
      • Camden, New Jersey, Forenede Stater, 08103
        • Cooper University Health Care - Camden /ID# 258133
      • Newark, New Jersey, Forenede Stater, 07102
        • Saint Michael's Medical Center /ID# 258802
      • Somers Point, New Jersey, Forenede Stater, 08244
        • South Jersey Infectious Disease /ID# 257840
    • New Mexico
      • Albuquerque, New Mexico, Forenede Stater, 87106
        • The University of New Mexico /ID# 257533
    • New York
      • Syracuse, New York, Forenede Stater, 13215
        • Suny Upstate University Hospital Community Campus /ID# 257847
      • The Bronx, New York, Forenede Stater, 10461
        • Jacobi Medical Center /ID# 257849
      • The Bronx, New York, Forenede Stater, 10467
        • Montefiore Medical Center /ID# 257792
    • North Carolina
      • Greenville, North Carolina, Forenede Stater, 27834
        • East Carolina University - Brody School of Medicine /ID# 257544
      • Winston-Salem, North Carolina, Forenede Stater, 27157
        • Atrium Health Wake Forest Baptist Medical Center /ID# 257542
    • Texas
      • Austin, Texas, Forenede Stater, 78705-3326
        • Central Texas Clinical Research /ID# 256920
      • Dallas, Texas, Forenede Stater, 75208-4599
        • Prism Health North Texas - Oak Cliff Health Center /ID# 256933
      • Dallas, Texas, Forenede Stater, 75246
        • North Texas Infectious Diseases Consultants, P.A /ID# 257592
      • Dallas, Texas, Forenede Stater, 75390-7208
        • University of Texas Southwestern Medical Center /ID# 257551
      • Fort Worth, Texas, Forenede Stater, 76104
        • Texas Center for Infectious Disease Associates /ID# 257183
      • Houston, Texas, Forenede Stater, 77098-3900
        • The Crofoot Research Center, Inc /ID# 256921
      • Longview, Texas, Forenede Stater, 75605
        • DCOL Center for Clinical Research /ID# 257093
    • Wisconsin
      • Milwaukee, Wisconsin, Forenede Stater, 53226
        • Wisconsin Medical Center /ID# 257498
      • Paris, Frankrig, 75012
        • AP-HP - Hopital Saint-Antoine /ID# 258090
      • Paris, Frankrig, 75020
        • AP-HP - Hopital Tenon /ID# 258091
      • Modena, Italien, 41124
        • Azienda Ospedaliero-Universitaria di Modena /ID# 257411
    • Milano
      • Milan, Milano, Italien, 20132
        • IRCCS Ospedale San Raffaele /ID# 259820
      • Milan, Milano, Italien, 20162
        • ASST Grande Ospedale Metropolitano Niguarda /ID# 257410
    • Napoli
      • Naples, Napoli, Italien, 80131
        • Azienda Ospedaliera Universitaria Federico II - Naples /ID# 257412
      • Tokyo, Japan, 108-8639
        • IMSUT Hospital, The Institute of Medical Science, The University of Tokyo /ID# 265344
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan, 460-0001
        • NHO Nagoya Medical Center /ID# 261433
    • Osaka
      • Osaka, Osaka, Japan, 540-0006
        • National Hospital Organization Osaka National Hospital /ID# 261520
    • Kuyavian-Pomeranian Voivodeship
      • Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polen, 85-030
        • Wojewodzki Szpital Obserwacyjno-Zakazny im. Tadeusza Browicza /ID# 259184
    • Pomeranian Voivodeship
      • Gdansk, Pomeranian Voivodeship, Polen, 80-405
        • Punkt Zdrowia /ID# 257950
      • San Juan, Puerto Rico, 00909-1711
        • Clinical Research Puerto Rico /ID# 256956
      • San Juan, Puerto Rico, 00909
        • HOPE Clinical Research /ID# 257487
      • Barcelona, Spanien, 08036
        • Hospital Clinic de Barcelona /ID# 257269
      • Madrid, Spanien, 28034
        • Hospital Universitario Ramon y Cajal /ID# 257266
      • Madrid, Spanien, 28046
        • Hospital Universitario La Paz /ID# 257170
    • Barcelona
      • Badalona, Barcelona, Spanien, 08916
        • Hospital Universitario Germans Trias i Pujol /ID# 257268
    • Gauteng
      • Johannesburg, Gauteng, Sydafrika, 2001
        • Wits RHI Research Centre /ID# 257354
      • Johannesburg, Gauteng, Sydafrika, 2013
        • Perinatal HIV Research Unit (PHRU) /ID# 257350
      • Johannesburg, Gauteng, Sydafrika, 2092
        • Clinical HIV Research Unit (CHRU) /ID# 257358
      • Johannesburg, Gauteng, Sydafrika, 2193
        • Ezintsha Research Centre /ID# 257391
      • Berlin, Tyskland, 10439
        • zibp-Zentrum fuer Infektiologie /ID# 257110
    • Hesse
      • Frankfurt am Main, Hesse, Tyskland, 60596
        • Infektiologikum /ID# 257112
    • North Rhine-Westphalia
      • Bonn, North Rhine-Westphalia, Tyskland, 53127
        • Universitaetsklinikum Bonn /ID# 257113

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 70 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • A condition of general good health in the opinion of the investigator, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG).
  • Must be on antiretroviral therapy (ART) for at least 12 months prior to screening and on a stable ART regimen for at least 8 weeks prior to screening (current ART regimen cannot include an Non-nucleoside reverse transcriptase inhibitor [NNRTI] or long-acting ART).
  • Negative human immuno-deficiency virus (HIV)-2 antibody (Ab)
  • Cluster of differentiation 4 (CD4+) T cell count >= 500 cells/μL at screening and no known evidence of CD4+ T cell count < 500 cells/μL in the last 12 months prior to screening
  • Participant must have plasma HIV-1 ribonucleic acid (RNA) below the lower limit of quantitation (LLOQ) at screening and for at least 12 months prior to screening

Exclusion Criteria:

  • Prior exposure to long acting antiretrovirals within 24 weeks or within a period defined by 5 half-lives, whichever is longer, prior to randomization and prior to the first dose of study drug.
  • History of CD4+ T cell nadir of <= 200 cells/μL during chronic HIV infection.
  • History of medical disorders (other than HIV-1 infection) that, in the opinion of the investigator, might expose the participant to undue risk of harm, confound study outcomes or prevent the participant from completing the study.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Arm A: Placebo

Participants will receive budigalimab placebo on Day 1, and Weeks 2, 4, and 6 in combination with ABBV-382 matching placebo on Day 1 and Weeks 4 and 8.

IV Infusion

IV Infusion

Eksperimentel: Arm B: Budigalimab Dose A

Participants will receive budigalimab Dose A on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 matching placebo Day 1 and Weeks 4 and 8.

IV Infusion

Intravenous (IV) Infusion

Andre navne:
  • ABBV-181

Subcutaneous (SC) Injection

Andre navne:
  • ABBV-181
Eksperimentel: Arm C: ABBV-382 Dose A

Participants will receive budigalimab placebo on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 Dose A on Day 1 and Weeks 4 and 8.

IV Infusion

IV Infusion

Eksperimentel: Arm D: Budigalimab Dose A + ABBV-382 Dose B

Participants will receive budigalimab Dose A on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 Dose B on Day 1 and Weeks 4 and 8.

Intravenous (IV) Infusion

Andre navne:
  • ABBV-181

Subcutaneous (SC) Injection

Andre navne:
  • ABBV-181

IV Infusion

Eksperimentel: Arm E: Budigalimab Dose A + ABBV-382 Dose A

Participants will receive budigalimab Dose A on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 Dose A on Day 1 and Weeks 4 and 8.

Intravenous (IV) Infusion

Andre navne:
  • ABBV-181

Subcutaneous (SC) Injection

Andre navne:
  • ABBV-181

IV Infusion

Eksperimentel: Arm F: Budigalimab Dose B

Participants will receive open-label budigalimab Dose B on Day 1 and Weeks 2, 4, and 6 (Note, no ABBV-382 or placebo will be administered).

Intravenous (IV) Infusion

Andre navne:
  • ABBV-181

Subcutaneous (SC) Injection

Andre navne:
  • ABBV-181

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Participants With Viral Control Without Antiretroviral Therapy (ART) Restart
Tidsramme: Week 24

Percentage of participants who achieve viral control (viral load < 1000 copies/mL) without ART restart at Week 24.

Week 24
Number of Participants With Adverse Events (AEs)
Tidsramme: Up to approximately Week 112

An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Up to approximately Week 112

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Median Peak Log10 Viral Load (At Rebound) Prior to Re-Starting ART
Tidsramme: Up to 112 weeks

The median peak log10 viral load (at rebound) before re-starting ART.

Up to 112 weeks
Median Time to First Rebound to ≥ 1000 Copies/mL During ART Interruption
Tidsramme: Up to 112 weeks

The median time to first rebound to ≥ 1000 copies/mL during ART interruption.

Up to 112 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: ABBVIE INC., AbbVie

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

12. oktober 2023

Primær færdiggørelse (Faktiske)

22. september 2025

Studieafslutning (Faktiske)

22. september 2025

Datoer for studieregistrering

Først indsendt

5. september 2023

Først indsendt, der opfyldte QC-kriterier

5. september 2023

Først opslået (Faktiske)

13. september 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

4. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • M19-965
  • 2023-505900-53-00 (Anden identifikator: EU CT)
  • 2023 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

IPD-delingstidsramme

For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

IPD-delingsadgangskriterier

To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner